37538-67-3

Usage

Uses

Used in Pharmaceutical Industry:
Pyrido[3,2-d]pyrimidin-4(1H)-one (9CI) is used as a key intermediate in the synthesis of various pharmaceuticals for its potential biological activity. Its heterocyclic structure allows for the development of new drugs with specific therapeutic targets.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, Pyrido[3,2-d]pyrimidin-4(1H)-one (9CI) is employed as a building block for the design and synthesis of novel compounds with potential therapeutic applications. Its structural flexibility enables the creation of diverse chemical entities for drug discovery and optimization.
Used in Organic Synthesis:
Pyrido[3,2-d]pyrimidin-4(1H)-one (9CI) is utilized as a versatile starting material in organic synthesis, allowing for the preparation of a wide range of organic compounds with various applications, including but not limited to, agrochemicals, dyes, and other specialty chemicals.

Upstream product

• 1462-86-8 3-amino-pyridine-2-carboxylic acid 
• 77287-34-4 formamide 
• 875233-01-5 pyrido[3,2-d]pyrimidin-4-amine 
• 50608-99-6 3-amino-pyridine-2-carboxylic acid amide 
• 122-51-0 orthoformic acid triethyl ester 
• 171178-21-5 6-chloro-3-nitropyridine-2-carboxamide 
• 463-52-5 formamidine 
• 175358-01-7 3-amino-6-chloro-pyridine-2-carboxylic acid amide 
• 873398-21-1 1H-pyrido[3,2-d]pyrimidine-2,4-dithione 
• 37538-68-4 pyrido<3,2-d>pyrimidine-2,4(1H,3H)-dione 
• 873398-20-0 4-amino-1H-pyrido[3,2-d]pyrimidine-2-thione 
• 39551-54-7 2,4-dichloropyrido[3,2-d]-pyrimidine 
• 93683-65-9 6-chloro-3-nitropicolinonitrile 

Downstream Products

• 51674-77-2 4-chloropyrido<3,2-d>pyrimidine 
• 884484-88-2 3-benzyloxy-2-[2-hydroxy-3-(4-oxo-4H-pyrido[3,2-d]pyrimidin-3-yl)-propyl]-piperidine-1-carboxylic acid benzyl ester 
• 51674-90-9 4-hydrazinopyrido(3,2-d)pyrimidine 
• 1312757-56-4 C₂₉H₃₀N₄O₅ 
• 175358-02-8 4,6-dichloropyrido<3,2-d>pyrimidine 
• 1420618-39-8 C₂₄H₁₈ClN₅O 

Relevant academic research and scientific papers

ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT

The present invention concerns a compound of following general formula (I): where: either R is an R1 group and R′ is an -A1-Cy1 group, or R is an -A1-Cy1 group and R′ is an R1 group, R1 particularly being H or (C1-C6)alkyl group;A1 being an —NH— radical or —NH—CH2— radical;Cy1 particularly being a phenyl group,A is a fused (hetero)aromatic ring having 5 to 7 atoms, for use for treating cancer.

Design, synthesis and bioactivity evaluation of 4,6-disubstituted pyrido[3,2-d]pyrimidine derivatives as mnk and HDAC inhibitors

Both HDACs and Mnks play important role in translating multiple oncogenic signaling pathways during oncogenesis. As HDAC and Mnk are highly expressed in a variety of tumors; thus simultaneous inhibit HDAC and Mnk can increase the inhibition of tumor cell proliferation and provide a new way of inhibiting tumor growth. Based on the previous work and the merge pharmacophore method; we designed and synthesized a series of 4,6-disubstituted pyrido[3,2-d]pyrimidine derivatives as HDAC and Mnk dual inhibitors. Among them; compound A12 displayed good HDAC and Mnk inhibitory activity. In vitro antiproliferative assay; compound A12 exhibited the best antiproliferative activity against human prostate cancer PC-3 cells. Docking study revealed that the pyrido[3,2-d]pyrimidine framework and hydroxamic acid motif of compound A12 were essential for maintaining the activity of HDAC and Mnk. These result indicated that A12 was a potent Mnk /HDAC inhibitor and will be further researched.

CRYSTALLINE FORMS OF SELETALISIB

Crystalline forms of seletalisib, designated as Form B and Form F and characterized herein, being selective inhibitors of PI3 kinase enzymes, in particular of the human ΡΒΚδ isoform, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor

Following the discovery of the very high inhibitory ability of the 4-[(3-bromophenyl)amino]-quinazolines against the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) (e.g., 3, IC50 0.029 nM), four series of related pyrido[d]pyrimidines bearing electron-donating groups at the 6- or 7-positions have been synthesized and evaluated. The compounds were prepared by nucleophilic substitution of the corresponding 6- and 7-fluoro analogues. While members of all series showed potent inhibitory activity against isolated EGFR, there were important differences between the different isomeric pyrido[d]pyrimidines and the parent quinazolines. Overall, the [3,4-d] and [4,3-d] series were the most potent, followed by the [3,2-d] compounds, with the [2,3-d] analogues being least active. Whereas in the parent quinazoline series the addition of steric bulk to a 6- or 7-NH2 substituent (i.e., NHMe and NMe2 groups) dramatically decreased potency, no such trend was discernable in the [3,2-d] series. Furthermore, in the 7-substituted pyrido[4,3-d]- and 6-substituted pyrido[3,4-d]pyrimidine series, and to a limited extent in the 7-substituted pyrido[2,3-d] series, such substitution increased potency dramatically, to the extent that the 7-(methylamino)pyrido[4,3-d]pyrimidine (5f) (IC50 0.13 nM) and 6-(methylamino)pyrido[3,4-d]pyrimidine (7f) (IC50 0.008 nM) constitute important new leads. Selected compounds were evaluated for their ability to inhibit EGFR autophosphorylation in A431 cells, and a positive quantitative correlation was found between this activity and inhibitory activity against the isolated enzyme.

Fungicidal use of pyridopyrimidine, pteridine, pyrimidopyrimidine, pyrimidopyridazine, and pyrimido-1,2,4-triazine derivatives

Fungicidal compositions contain as active ingredient a 4-substituted-pyrido[3,2-d]pyrimidine, -pyrido[4,3-d]pyrimidine, -pyrido[3,4-d]pyrimidine, pyrido[2,3-d]pyrimidine, -pteridine, -pyrimido[4,5-d]pyrimidine, -pyrimido[4,5-c]pyridazine, -pyrimido[5,4-d]